Organisation paid for research Program year 2025 Source: CMS Open Payments

Creighton University

Neither a doctor nor a teaching hospital

Research payments

$1,677,226

385 payments

Through program year 2025, Creighton University is reported as receiving $1,677,226 in research payments, across 385 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$215,628	54
2024	Research	$184,611	37
2023	Research	$127,402	18
2022	Research	$165,697	66
2021	Research	$350,595	61
2020	Research	$250,391	81
2019	Research	$382,901	68

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $353,616 25 payments
Pfizer Inc. $275,669 71 payments
GlaxoSmithKline, LLC. $272,593 86 payments
Sanofi Pasteur Inc. $199,574 51 payments
United Therapeutics Corporation $111,860 46 payments
GRT US Holding, Inc. $106,421 5 payments
Shionogi Inc $102,288 16 payments
Insmed, Inc. $57,525 36 payments
Novartis Pharmaceuticals Corporation $54,396 3 payments
DENTSPLY DeTrey GmbH $30,622 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $178,630 25 payments
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $142,844 33 payments
PDE4 Phase III trial in IPF patients $112,768 2 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $108,138 56 payments
Kf7013-04 $106,421 5 payments
A Phase 2 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine Given With Or Separately From 13Valent Pneumococcal Conjugate Vaccine in Healthy Infants $87,661 37 payments
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $80,226 24 payments
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $72,436 29 payments
A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm $70,180 5 payments
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) $62,534 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.